Beneficial ownership — 13D / 13G
87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Randall Moreadith | SER Serina Therapeutics, Inc. | 13D | 6.8% | Mar 26, 2024 | 2y |
| Socoservin Overseas SPF S.a.r.l. | GPRK GeoPark Ltd | 13G/A | 5.22% | Dec 31, 2023 | 2y |
| Sumitomo Chemical Co., Ltd. | ROIV Roivant Sciences Ltd. | 13G/A | 0% | Apr 2, 2024 | 2y |
| New Enterprise Associates 14, L.P. | ADAPY Adaptimmune Therapeutics PLC | 13D/A | 6.7% | Apr 1, 2024 | 2y |
| Charles W. Ergen | ECHO EchoStar CORP | 13D/A | 54% | Apr 1, 2024 | 2y |
| BROWNING WEST LP | GIL Gildan Activewear Inc. | 13D/A | 5% | Apr 1, 2024 | 2y |
| Brookstone Capital Management | AAPR Innovator ETFs Trust | 13G | 13.41% | Mar 31, 2024 | 2y |
| Brookstone Capital Management | AAPR Innovator ETFs Trust | 13G/A | 3.01% | Mar 31, 2024 | 2y |
| General Electric Co | GEHC GE HealthCare Technologies Inc. | 13G/A | 6.7% | Mar 31, 2024 | 2y |
| Brookstone Capital Management | AAPR Innovator ETFs Trust | 13G | 17.55% | Mar 31, 2024 | 2y |
| Brookstone Capital Management | AAPR Innovator ETFs Trust | 13G/A | 2.12% | Mar 31, 2024 | 2y |
| David J. Lubar | HNRG Hallador Energy Co | 13D/A | 15.09% | Mar 29, 2024 | 2y |
| Newhouse Broadcasting Corporation | WBD Warner Bros. Discovery, Inc. | 13D/A | 8.12% | Mar 29, 2024 | 2y |
| Silver Lake West HoldCo, L.P. | EDR Endeavor Group Holdings, Inc. | 13D/A | 45.4% | Mar 29, 2024 | 2y |
| Maurice Marciano | GES Guess, Inc. | 13D/A | 21.5% | Mar 28, 2024 | 2y |
| Paul Marciano | GES Guess, Inc. | 13D/A | 37.2% | Mar 28, 2024 | 2y |
| AKIN THOMAS B | MHLA Maiden Holdings, Ltd. | 13G/A | 7.2% | Mar 28, 2024 | 2y |
| AKIN THOMAS B | HIPO Hippo Holdings Inc. | 13G | 2.2% | Mar 28, 2024 | 2y |
| BML Investment Partners, L.P. | TIL Instil Bio, Inc. | 13G | 5.3% | Mar 22, 2024 | 2y |
| John J. Bello | REED Reed's, Inc. | 13D/A | 15.2% | Mar 7, 2024 | 2y |
| KVC Sponsor LLC | KVACF Keen Vision Acquisition Corp. | 13G | 22.8% | Dec 31, 2023 | 2y |
| Maximilian Thyssen | SFRX Seafarer Exploration Corp | 13G/A | 7.48% | Dec 31, 2023 | 2y |
| KOONCE CALVIN SCOTT | VSEC Vse Corp | 13D/A | 11.9% | Dec 15, 2020 | 2y |
| Vintage Investments 5 L.P. | CTV Innovid Corp. | 13G/A | 3.3% | Apr 1, 2024 | 2y |
| Logos Global Management LP | NXTC NextCure, Inc. | 13G | 7.2% | Apr 1, 2024 | 2y |
| EquityLine Alternate Assets GP Inc. | MBAI MBody AI Ltd. | 13D | 13% | Apr 1, 2024 | 2y |
| H.I.G. Growth AdTheorent, LLC | ADTH AdTheorent Holding Company, Inc. Common Stock | 13D/A | 37.5% | Apr 1, 2024 | 2y |
| Fairmount Funds Management LLC | DNTH Dianthus Therapeutics, Inc. | 13D/A | 9.99% | Apr 1, 2024 | 2y |
| STG III, L.P. | TBLA Taboola.com Ltd. | 13G/A | 2.5% | Apr 1, 2024 | 2y |
| Simeon A. Thibeaux | RRBI Red River Bancshares Inc | 13G/A | 15.1% | Mar 31, 2024 | 2y |
| Ryan Michael Pratt | GUER Guerrilla RF, Inc. | 13D/A | 9.88% | Mar 28, 2024 | 2y |
| Saba Capital Management, L.P. | SABA Saba Capital Income & Opportunities Fund II | 13D/A | 12.61% | Mar 28, 2024 | 2y |
| Salem Investment Partners V, Limited Partnership ( ) | GUER Guerrilla RF, Inc. | 13D/A | 17.2% | Mar 28, 2024 | 2y |
| BAKER BROS. ADVISORS LP | KYMR Kymera Therapeutics, Inc. | 13D | 9.8% | Mar 28, 2024 | 2y |
| AMB Investments LLC | GUER Guerrilla RF, Inc. | 13D/A | 14.12% | Mar 28, 2024 | 2y |
| Comcast Ventures, LP | ZPTA Zapata Quantum, Inc. | 13G | 8.7% | Mar 28, 2024 | 2y |
| TAKEDA PHARMACEUTICAL CO LTD | PHAT Phathom Pharmaceuticals, Inc. | 13D/A | 5.4% | Mar 28, 2024 | 2y |
| Fairmount Funds Management LLC | APGE Apogee Therapeutics, Inc. | 13D/A | 9.99% | Mar 28, 2024 | 2y |
| Fairmount Funds Management LLC | VRDN Viridian Therapeutics, Inc.DE | 13D/A | 18.64% | Mar 28, 2024 | 2y |
| Fairmount Funds Management LLC | COGT Cogent Biosciences, Inc. | 13D/A | 9.9% | Mar 28, 2024 | 2y |
| Avram Glazer Irrevocable Exempt Trust | VATE INNOVATE Corp. | 13D/A | 29.1% | Mar 28, 2024 | 2y |
| TCG Crossover GP I, LLC | KALV KalVista Pharmaceuticals, Inc. | 13D/A | 3.2% | Mar 28, 2024 | 2y |
| Runa Capital Opportunity I (GP) | MRDB MariaDB plc | 13D/A | 8.7% | Mar 27, 2024 | 2y |
| Divisadero Street Capital Management, LP | STIM Neuronetics, Inc. | 13G | 5.2% | Mar 26, 2024 | 2y |
| Lynx1 Capital Management LP | IBIO iBio, Inc. | 13G | 9.99% | Mar 26, 2024 | 2y |
| TRUMP DONALD J | DJT Trump Media & Technology Group Corp. | 13D | 57.6% | Mar 25, 2024 | 2y |
| L1 Capital Global Opportunities Master Fund, Ltd. | SINT Sintx Technologies, Inc. | 13G | 8.8% | Mar 25, 2024 | 2y |
| Atlas Venture Fund X, L.P. | QTTB Q32 Bio Inc. | 13D | 7.2% | Mar 25, 2024 | 2y |
| Stavros G. Vizirgianakis | APYX Apyx Medical Corp | 13D | 5.04% | Mar 25, 2024 | 2y |
| Venrock Healthcare Capital Partners III, L.P. | AQST Aquestive Therapeutics, Inc. | 13G | 6.5% | Mar 22, 2024 | 2y |